溶癌病毒为人类征服癌症带来了新的希望。动物dsRNA BTV同科的人RV是最有希望的溶癌病毒，但是，却有对人体的天然毒性，且人体几乎都有抗RV抗体。人类已结论：动物BTV不能在人正常细胞增殖，对人体安全。我们体内外研究表明：BTV能有效地靶向感染并杀死人癌细胞，安全性强、抗癌谱广，能用于个性化治疗、不存在RV毒性问题，具有发展成全新溶癌病毒之潜能。我们提出：基因突变使正常细胞转化成与其起源细胞特性和行为迥异的恶性细胞，衍生出了对某些异源病毒感染的条件，成为其靶向攻击的目标；而不同的遗传背景又使同种病毒致不同癌细胞归于不同的死亡模式。本项目将以RV为对照，较系统地研究BTV-16致不同人癌细胞死亡的特征及相关遗传背景，获取一组与其靶向抗癌相关的关键基因和可能信号通路，为溶癌BTV提供理论依据；亦为BTV临床研究和潜在的临床应用时肿瘤病例选择、治疗方案制定及个性化治疗设计提供可靠的科学数据。

Oncolytic virus is targeted to kill cancer cells virus, Brings new hope for human to conquer cancer cells. The dsRNA bluetongue virus (BTV), belonged to the same family of reovirus (RV), is the most promising Oncolytic virus. However, there is natural toxicity to human and the anti-RV antibody exists in almost every human body. The conclusion has early been made: The animal BTV can't proliferate in normal human cells, so that it is safe to human. The results further from our research in vitro and in vivo show that the BTV is able effectively to infect and specifically to kill cancer cells. When used, it is of great safety, broad anticancer spectrum, and can be for personalized treatment, does not produce the toxicity emerged as RV and so on. Namely, it possesses the potential developed into a new oncolytic virus. We think that the gene mutation causes the normal cells are transformed into the malignant cells with the characteristics and behavior different from their origin cells, so as to become the aim the oncolytic virus attacks because the conditions for infection with some heterologous virus was derived. And the different genetic background of different cancer cells causes themselves to die in different mode as infected with same viruses. In present project with RV as the control, a systematic study will be performed on the related genetic background of different cancer cells and their different death features induced by BTV-16, to obtain a set of key genes and possible signal pathway related targeting cancer cells, to found the theoretical basis for oncolytic BTV, to provide reliable scientific data for selection of tumor patient, determination of the treatment program and design of individualized treatment etc in BTV clinical research and potential clinical application.